eff Cancer Research Results
eff, efficacy: Click to Expand ⟱
| Source: |
| Type: |
Power to enhance an anti cancer effect
|
Lung, Lung Cancer: Click to Expand ⟱
Lung CSC (Cancer Stem Cells) markers (CD133, CD44, ALDHA1, Nanog and Oct4)
|
Scientific Papers found: Click to Expand⟱
| - |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
BC, |
MCF7 |
|
|
|
- |
in-vitro, |
Melanoma, |
A375 |
|
|
|
- |
in-vitro, |
Colon, |
HCT15 |
|
|
|
- |
in-vitro, |
Cerv, |
HeLa |
|
|
|
TrxR↓, eff↓, eff↓, other∅,
ROS↑, tumCV↓, MMP↓, TumCCA↑, PCNA↓, eff↓,
| - |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
Lung, |
L132 |
|
|
|
mtDam↑, ROS↑, Hif1a↑, LC3s↑, p62↑, eff↓,
mt-ROS↑, Apoptosis↑, Casp9↑, Bcl-2↓, eff↓, eff↑, H2O2↑, Dose↑,
| - |
in-vitro, |
Lung, |
H1299 |
|
|
|
- |
in-vitro, |
Lung, |
H460 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
Melanoma, |
A375 |
|
|
|
- |
in-vitro, |
Lung, |
H2030 |
|
|
|
- |
in-vitro, |
CRC, |
SW480 |
|
|
|
Glycolysis↓, lactateProd↓, PGK1↓, ALDOA↓, GLUT1↓, ENO1↓, ATP↓, Casp9↑, Casp3↑, cl‑PARP↑, PI3K/Akt↓, HK1↓, HK2↓, ROS↑, Apoptosis↑, eff↓, NADPH↓, PPP↓,
ROS↑, eff↓,
| - |
in-vitro, |
Lung, |
H1650 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vivo, |
NA, |
NA |
|
|
|
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP/DDIT3↑, p‑eIF2α↑, ICD↑, eff↑,
TumCG↓, Apoptosis↑, DR5↑, FasL↑, FADD↑, Casp8↑, cFLIP↓, Casp9↑, Casp3↑, cl‑PARP↑, MMP↓, BID↑, BAX↑, Cyt‑c↑, ROS↑, eff↓, AMPK↑,
| - |
in-vitro, |
Lung, |
H1975 |
|
|
|
- |
in-vivo, |
Lung, |
NA |
|
|
|
eff↑, TumCP↓, Apoptosis↑, cl‑Casp3↑, cl‑PARP↑, cl‑Casp9↑, p‑PI3K↓, p‑Akt↓, ROS↑, eff↓,
DR5↑, FADD↑, FasL↑, Casp8↑, cFLIP↓, Casp3↑, Casp9↑, cl‑PARP↑, MMP↓, BID↑, Cyt‑c↑, ROS↑, eff↓, AMPK↑, Apoptosis↑, TumCCA↑, DR5↑, FasL↑, DR4∅, cFLIP↓, FADD↑, MMPs↓,
Apoptosis↑, Casp3↑, Cyt‑c↑, MMP↓, p‑JNK↑, eff↓,
| - |
vitro+vivo, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
Nor, |
BEAS-2B |
|
|
|
- |
in-vitro, |
Lung, |
PC9 |
|
|
|
Dose↝, mt-ROS↑, p‑JNK↑, BAX↑, Cyt‑c↑, Casp↑, AntiTum↑, ER Stress↑, LDH↑, selectivity↑, Apoptosis↑, DNAdam↑, IRE1↑, XBP-1↑, CHOP/DDIT3↓, p‑eIF2α↓, GRP78/BiP↓, Ca+2↑, MMP↓, Bcl-2↓, Casp3↑, Casp9↑, eff↓, TumW↓, Weight↑, eff↑, eff↑,
AntiTum⇅, tumCV↓, Apoptosis↑, eff↓, COX2↑, PPARγ↑,
| - |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
OS, |
U2OS |
|
|
|
- |
in-vitro, |
CRC, |
HCT116 |
|
|
|
- |
in-vitro, |
CRC, |
HeLa |
|
|
|
- |
in-vivo, |
Ovarian, |
SKOV3 |
|
|
|
ROS↑, Trx↓, Apoptosis↑, TumCG↓, SUV39H↓, Hif1a↓, TumCP↓, eff↓, MMP↓, TumCG↓, Dose↝, toxicity↓,
selectivity↑, eff↑, ROS↑, Apoptosis↓, HDAC↓, MMP↓, cl‑PARP↑, eff↑, eff↓, i-GSH∅,
ROS↑, hTERT/TERT↓, Sp1/3/4↓, eff↓,
ROS↑, eff↓, p‑Akt↓, Casp3↑, Apoptosis↑,
NRF2↑, eff↓,
| - |
in-vitro, |
Lung, |
Calu-1 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
TumCG↓, MMP↓, ROS↑, GSH↓, eff↑, eff↓, eff↑, mtDam↑, Ca+2↑,
TumCG↓, TumAuto↑, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↑, ROS↑, eff↓,
| - |
vitro+vivo, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vitro, |
Pca, |
DU145 |
|
|
|
- |
in-vitro, |
Liver, |
HepG2 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
TumCP↓, TumMeta↓, p‑STAT3↓, JAK2↓, cSrc↓, JNK↑, p38↑, ERK↑, eff↓, ROS↑, cl‑PARP↑, TumCCA↑, Casp8↑, Casp9↑, Casp3↑, eff↑, Bcl-2↑, Bcl-xL↓, survivin↓, MMP9↓, COX2↓, IAP1↓, Dose?,
Bcl-2↓, Bcl-xL↓, Mcl-1↓, NOXA↑, PUMA↑, Dose↝, eff↓,
TumCMig↓, TumCI↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, BAX↑, Cyt‑c↑, ROS↑, MDA↑, GPx4↓, SOD↓, PI3K↓, Akt↓, eff↓,
MMP↓, p‑MAPK↑, ROS↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, eff↓,
| - |
in-vitro, |
GBM, |
GBM |
|
|
|
- |
in-vitro, |
Lung, |
NA |
|
|
|
mt-ROS↑, Casp3↑, selectivity↑, TumCD↑, ETC↓, H2O2↑, eff↓, GSH↑, MMP↓,
TrxR↓, eff↑, TumCCA↑, eff↓, ROS↑,
| - |
in-vitro, |
BC, |
MCF7 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
selectivity↑, ROS↑, SETBP1↓, cl‑Casp9↑, eff↓, FOSB↑,
| - |
in-vitro, |
PC, |
PANC1 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
Kidney, |
786-O |
|
|
|
- |
in-vitro, |
BC, |
SkBr3 |
|
|
|
ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1/CCND1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,
| - |
in-vitro, |
BC, |
MCF7 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
lymphoma, |
U937 |
|
|
|
eff↓, ROS↑, NKG2D↑,
ROS↑, EGFR↓, eff↓, TumCCA↑, γH2AX↑, DNAdam↑, eff↓,
Apoptosis↑, Pyro↑, Casp↑, cl‑PARP↑, GSDME↑, ROS↑, COX2↓, PDK1↓, Akt↓, ERK↓, eff↓, eff↓, eff↑,
| - |
in-vitro, |
Lung, |
H1975 |
|
|
|
- |
in-vitro, |
Lung, |
H1650 |
|
|
|
- |
in-vitro, |
Nor, |
CCD19 |
|
|
|
EGFR↓, selectivity↑, Casp↑, PARP↑, Apoptosis↑, ROS↑, eff↓, selectivity↑,
toxicity↝, eff↓, other↝, ROS↑, mtDam↑,
Showing Research Papers: 1 to 33 of 33
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 33
Pathway results for Effect on Cancer / Diseased Cells:
NA, unassigned(tgid=0) ⓘ
SUV39H↓, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
GPx4↓, 1, GSH↓, 1, GSH↑, 1, i-GSH∅, 1, H2O2↑, 2, HK1↓, 1, ICD↑, 1, MDA↑, 1, NRF2↑, 1, ROS↑, 25, mt-ROS↑, 3, SOD↓, 1, Trx↓, 1, TrxR↓, 2,
Mitochondria & Bioenergetics(tgid=3) ⓘ
ATP↓, 1, ETC↓, 1, MMP↓, 10, mtDam↑, 3, XIAP↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
ALDOA↓, 1, AMPK↑, 2, cMyc↓, 1, ENO1↓, 1, Glycolysis↓, 1, HK2↓, 1, lactateProd↓, 1, LDH↑, 1, NADPH↓, 1, PDK1↓, 1, PGK1↓, 1, PI3K/Akt↓, 1, PPARγ↑, 1, PPP↓, 1,
Cell Death(tgid=5) ⓘ
Akt↓, 2, p‑Akt↓, 2, Apoptosis↓, 1, Apoptosis↑, 15, BAD↑, 1, Bak↑, 1, BAX↑, 4, Bcl-2↓, 5, Bcl-2↑, 1, Bcl-xL↓, 2, BID↑, 2, Casp↑, 3, Casp3↑, 8, cl‑Casp3↑, 2, Casp8↑, 3, Casp9↑, 6, cl‑Casp9↑, 2, cFLIP↓, 3, Cyt‑c↑, 5, DR4∅, 1, DR5↑, 3, FADD↑, 3, FasL↑, 3, GSDME↑, 1, hTERT/TERT↓, 1, IAP1↓, 1, JNK↑, 1, p‑JNK↑, 2, p‑MAPK↑, 1, Mcl-1↓, 2, NOXA↑, 1, p38↑, 1, PUMA↑, 1, Pyro↑, 1, survivin↓, 3, TumCD↑, 1,
Kinase & Signal Transduction(tgid=6) ⓘ
cSrc↓, 1, Sp1/3/4↓, 2,
Transcription & Epigenetics(tgid=7) ⓘ
other↝, 1, other∅, 1, SETBP1↓, 1, tumCV↓, 2,
Protein Folding & ER Stress(tgid=8) ⓘ
CHOP/DDIT3↓, 1, CHOP/DDIT3↑, 1, p‑eIF2α↓, 1, p‑eIF2α↑, 1, ER Stress↑, 2, GRP78/BiP↓, 1, IRE1↑, 1, XBP-1↑, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
Beclin-1↑, 1, LC3‑Ⅱ/LC3‑Ⅰ↑, 1, LC3s↑, 1, p62↑, 1, TumAuto↑, 1,
DNA Damage & Repair(tgid=10) ⓘ
DNAdam↑, 2, PARP↑, 1, cl‑PARP↑, 9, PCNA↓, 1, γH2AX↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
cycD1/CCND1↓, 1, TumCCA↑, 6,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
cMET↓, 1, ERK↓, 1, ERK↑, 1, HDAC↓, 1, PI3K↓, 1, p‑PI3K↓, 1, p‑STAT3↓, 1, TumCG↓, 5,
Migration(tgid=13) ⓘ
Ca+2↑, 2, FOSB↑, 1, MMP9↓, 1, MMPs↓, 1, TumCI↓, 1, TumCMig↓, 1, TumCP↓, 4, TumMeta↓, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
EGFR↓, 3, Hif1a↓, 1, Hif1a↑, 1,
Barriers & Transport(tgid=15) ⓘ
GLUT1↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
COX2↓, 2, COX2↑, 1, JAK2↓, 1, PD-L1↑, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
Dose?, 1, Dose↑, 1, Dose↝, 3, eff↓, 36, eff↑, 12, selectivity↑, 6,
Clinical Biomarkers(tgid=22) ⓘ
EGFR↓, 3, hTERT/TERT↓, 1, LDH↑, 1, PD-L1↑, 1,
Functional Outcomes(tgid=23) ⓘ
AntiTum↑, 1, AntiTum⇅, 1, NKG2D↑, 1, toxicity↓, 1, toxicity↝, 1, TumW↓, 1, Weight↑, 1,
Total Targets: 137
Pathway results for Effect on Normal Cells:
Total Targets: 0
Scientific Paper Hit Count for: eff, efficacy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:15 Cells:% prod#:% Target#:961 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page